EWL
iShares MSCI Switzerland ETF
#11 of 13 in Developed Markets by own-history percentile (high → low)
Relative to SPY
Relative price history
EWL ÷ SPY, 10-year range, as of Sep 18, 2026
How the reading moved
These changes re-score an older EWL÷SPY ratio against today's 10-year window, so they show whether the relative price has drifted toward the highs or lows of its own history — not a peer ranking and not a return forecast.
- About one week: 0.0 pts (from 1.6% on Aug 31, 2026 to 1.6% now)
- About one month: -1.9 pts (from 3.5% on Jul 31, 2026 to 1.6% now)
Developed Markets
Where this sits among peers
Developed Markets · EWL highlighted · same axes as the category chart on the home page
Top holdings
Holdings snapshot as of Jul 17, 2026.
What moves this
EWL is dominated by a small number of large pharmaceutical and consumer-staples companies, which gives it a defensive earnings profile closer to a global healthcare/staples basket than to a typical country fund, and it has historically traded at a premium to broader Europe as a result.
FAQ
Why does Switzerland trade at a premium to the rest of Europe?
Its index is concentrated in a few large, globally diversified pharmaceutical and staples companies with earnings stability more typical of those sectors than of a country-focused index.
Is this fund really just a bet on a couple of large pharma companies?
Pharmaceutical and food/consumer-staples giants make up a large share of the index, so yes — the fund's behavior leans heavily on a small number of names.
Does the Swiss franc's safe-haven status affect this ETF?
The franc has historically strengthened during periods of global stress, which can support this dollar-denominated fund's relative price during risk-off periods even if underlying earnings haven't changed.
Developed Markets